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Abstract
Background: Evidence of genetic association between the NRG1 (Neuregulin-1) gene and schizophrenia is now
well-documented. Furthermore, several recent reports suggest association between schizophrenia and single-
nucleotide polymorphisms (SNPs) in ERBB4, one of the receptors for Neuregulin-1. In this study, we have
extended the previously published associations by investigating the involvement of all eight genes from the ERBB
and NRG families for association with schizophrenia.
Methods: Eight genes from the ERBB and NRG families were tested for association to schizophrenia using a
collection of 396 cases and 1,342 blood bank controls ascertained from Aberdeen, UK. A total of 365 SNPs were
tested. Association testing of both alleles and genotypes was carried out using the fast Fisher's Exact Test (FET).
To understand better the nature of the associations, all pairs of SNPs separated by ≥ 0.5 cM with at least nominal
evidence of association (P < 0.10) were tested for evidence of pairwise interaction by logistic regression analysis.
Results: 42 out of 365 tested SNPs in the eight genes from the ERBB and NRG gene families were significantly
associated with schizophrenia (P < 0.05). Associated SNPs were located in ERBB4 and NRG1, confirming earlier
reports. However, novel associations were also seen in NRG2, NRG3 and EGFR. In pairwise interaction tests,
clear evidence of gene-gene interaction was detected for NRG1-NRG2, NRG1-NRG3 and EGFR-NRG2, and
suggestive evidence was also seen for ERBB4-NRG1, ERBB4-NRG2, ERBB4-NRG3 and ERBB4-ERBB2. Evidence
of intragenic interaction was seen for SNPs in ERBB4.
Conclusion: These new findings suggest that observed associations between NRG1 and schizophrenia may be
mediated through functional interaction not just with ERBB4, but with other members of the NRG and ERBB
families. There is evidence that genetic interaction among these loci may increase susceptibility to schizophrenia.
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Background
Schizophrenia is a complex psychiatric disorder which
affects 0.5–1% of the world wide adult population. A
number of putative schizophrenia susceptibility genes
have been identified recently [1,2]. Genomewide linkage
analysis on large Icelandic pedigrees showed evidence for
linkage with an initial LOD score of 3 on chromosome
8p13, which led to the identification of the Neuregulin-1
gene (NRG1) as a potential genetic risk factor (O.R. = 2)
for schizophrenia [3]. The association was confirmed in a
large Scottish case control data set [4], and both studies
indicated a core haplotype (HAPICE) as the DNA variation
carrying most of the risk for schizophrenia. Subsequently,
15 published studies in schizophrenia data sets of various
Asian and Caucasian ethnic backgrounds have detected
association in NRG1 SNPs or haplotypes, while only four
studies were not able to replicate the association (see [5]
and [6] for a comprehensive review). The association
studies reported thus far strongly suggest a true effect of
NRG1 as a susceptibility gene for schizophrenia. How-
ever, some caution should be exercised before calling
NRG1 a true "schizophrenia gene" due to the lack of a
known functional effect of the identified NRG1 variants,
the allelic heterogeneity reported across several studies
and the multiple SNPs and haplotypes analysed in differ-
ent studies. Nonetheless, several recent publications
report an association between schizophrenia and ErbB4,
one of the receptors for NRG1 [7-9]. This provides indirect
evidence supporting NRG1 association with schizophre-
nia and a role for aberrant neuregulin signalling in this
disorder.
The Neuregulin-ErbB signalling network is involved in a
multitude of processes in the developing and adult brain.
Neuregulins for example promote neuronal migration
and differentiation, regulate the expression of neurotrans-
mitter receptors, influence glial proliferation, survival and
differentiation and play a role in synaptic plasticity.
The neuregulins (NRG) are cell-cell signalling proteins
that are ligands for receptor tyrosine kinases of the ErbB
family. Whereas NRG1 is known to play essential roles in
nervous system and heart development, as well as in the
adult brain (see above), less is known about the other
members of the NRG gene family, NRG2, -3 and -4
[10,11].
The ErbB family comprises four homologous typeI recep-
tor tyrosine kinases (RTKs). The EGFR (epidermal growth
factor receptor, HUGO name for ErbB1), ErbB3 and
ErbB4 receptors can bind ligands, whereas ErbB2 lacks a
ligand binding domain and functions as a preferred and
very potent co-receptor. ErbB3 is devoid of an active
kinase domain. ErbB4 is the only ErbB family member
that binds all four neuregulins, as well as several proteins
that had originally been identified as EGFR ligands (Fig.
1). Furthermore, NRG1 and NRG2 can also bind to ErbB3.
In contrast, none of the neuregulins bind to EGFR which
instead binds unrelated ligands such as EGF, amphiregu-
lin and others (see Fig. 1).
Ligand binding to the extracellular domain of ErbB family
members leads to receptor homo-and heterodimerisation
and activation of various intracellular signalling pathways
such as the Ras-Raf-MAPK and the PI-3 Kinase pathways
(reviewed in [12]).
In order to investigate the involvement of neuregulin
pathway genes in schizophrenia, beyond the previously
published association with NRG1 and ERBB4, we have
tested all eight genes from the ERBB and NRG families for
association with schizophrenia. We have investigated
both single genes and gene-gene interactions, using a col-
lection of schizophrenia cases and blood bank controls
from Aberdeen, Scotland.
Methods
Subjects
396 Caucasian cases were ascertained in Aberdeen, Scot-
land. All have a basic diagnosis of schizophrenia or
schizoaffective disorder according to the Operational Cri-
Binding specificities of ErbB receptor family ligands Figure 1
Binding specificities of ErbB receptor family ligands. 
EGF (epidermal growth factor), AREG (amphiregulin) and 
TGFA (transforming growth factor-α) bind EGFR (ErbB1) 
only. BTC (Betacellulin), HBEGF (heparin-binding EGF-like 
growth factor) and EREG (Epiregulin) bind EGFR and ErbB4. 
NRG1 and NRG2 bind ErbB3 and ErbB4. NRG3 and NRG4 
are specific for ErbB4. Receptors form homo- and het-
erodimers after ligand-binding (not shown). As indicated (X), 
ErbB2 has no ligand-binding capacity and ErbB3 has no active 
kinase domain. Only NRG1-4 and ERBB1-4 genes were 
investigated in this study. (Modified from [46]).Behavioral and Brain Functions 2007, 3:31 http://www.behavioralandbrainfunctions.com/content/3/1/31
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teria Checklist (OPKRIT). 285 of the cases were male; 111
were female. The mean recruitment age was 44 yr with a
standard deviation of 14 yr.
1342 Controls were ascertained as a series of anonymous
blood donors from Aberdeen, Scotland. Due to subject
anonymity, characteristics such as schizophrenia- status,
age and ethnic group could not be determined. However
at the time of sample collection, the Aberdeen Blood
Transfusion Service made a concerted effort to exclude any
non-Caucasian samples. At the time of this study, non-
Caucasians constituted around 2% of the Aberdeen popu-
lation but a lower percentage of Aberdeen blood donors.
724 control subjects were male; 618 were female.
Informed consent was obtained for all subjects involved
in this study.
As calculated by the power equations of Risch and Teng
[13], under a multiplicative model of association, a sam-
ple of 400 cases and 1300 controls has 80% power to
detect disease association at an α = 0.05 significance level
for SNPs having a genotypic relative risk of 1.5 [14] and
susceptibility allele frequencies between 0.07 and 0.9.
Polymorphism selection and genotyping
SNPs from each gene were selected at an approximate
spacing of 1 SNP every 10 kb. Six of these SNPs are located
in potentially functional regions of the genes, five in
exons and one in a promoter region (Table 1). Among the
SNPs that are in exons, two are synonymous, but the other
three produce amino acid changes. The size of these genes
varied greatly, from 23 kb to 1110 kb, and there was a cor-
responding variation in the number of SNPs analysed,
from 4 to 109 (for further details see Table 2, in the
Results section).
Genotyping was performed using a modification of the
single base chain extension assay previously described
[15], at GlaxoSmithKline, UK. A SNP passed QC if over
80% of genotype calls were successful.
Statistical analysis
All SNPs were tested for departure from Hardy Weinberg
equilibrium (HWE) in controls using a chi squared test
with one degree of freedom. This test compares the
expected genotype frequencies calculated from the allele
frequencies, with observed genotype frequencies. A depar-
ture from HWE in controls may indicate errors in the data.
Association testing of both alleles and genotypes was car-
ried out using the 'PROC FREQ' fast Fisher's Exact Test
(FET) procedure in the statistical software package
SASv8.2 (SAS Institute Inc., Cary, NC, USA). The Fast
Fisher's Exact Test computes exact P-values for general
contingency tables using the network algorithm devel-
oped by [16]. The network algorithm provides substantial
advantages over direct enumeration and is rapid and accu-
rate. The exact test is used in preference to the asymptotic
chi-square P-value as it is more accurate at loci where the
minor allele frequency is low.
In order to model and test for interactions between SNPs
in different candidate genes, standard logistic regression
analysis was performed using the statistical software pack-
age R (The R Project for Statistical Computing, [17]). Fol-
lowing Cordell [18] the model tested had the following
form:
log(p/(1-p)) = μ + a1 x1 + d1 z1 + a2 x2 + d2 z2 + iaa x1 x2 + iad x1 
z2 + ida z1 x2 + idd z1 z2
where x1, x2, z1 and z2 are variables determined by the gen-
otype under consideration, and μ, a1, a2, d1, d2, iaa, iad, ida
and idd are parameters to be estimated. Here, genotypes at
two SNPs are being modelled and, for each of the 9 possi-
ble genotype combinations at the two SNPs, p is the pro-
portion of subjects with the genotype who are cases and
(1-p) is the proportion of subjects with the genotype who
are controls. The first five terms in the equation represent
the effects of the two SNPs on log(p/(1-p)) if there is no
statistical interactions between the two SNPs. A non-zero
value for one or more of the remaining four coefficients
(iaa, iad, ida, idd) indicates the presence of interaction. Statis-
Table 1: SNPs in potentially functional gene regions included in the present study.
Gene Polymorphism1 Chromosome Position2 Region Base change Amino acid 
change
EGFR rs2072454 7 54988557 Exon 4 C/T Asn/Asn
ERBB2 rs1801200 17 35133114 Exon 20 A/G Val/Ile
ERBB2 rs1058808 17 35137563 Exon 30 C/G Pro/Ala
ERBB4 rs3748962 2 212077370 Exon 27 C/T Val/Val
NRG1 rs6994992 8 31615123 Promoter C/T -
NRG1 rs3924999 8 32572900 Exon 2 C/T Gln/Arg
1Polymorphism names are taken from the dbSNP website, [47].
2From map NCBI 35.Behavioral and Brain Functions 2007, 3:31 http://www.behavioralandbrainfunctions.com/content/3/1/31
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tical significance was assessed by a likelihood ratio test,
comparing the full model above with a reduced model in
which the last four terms are absent (i.e. in which the coef-
ficients iaa, iad, ida and idd are all set to zero).
A significant interaction effect in the logistic regression
analysis indicates that the combined effect of the two
SNPs is significantly different from the sum of their indi-
vidual effects. Pair-wise interactions may be of three types,
namely 'and', 'or' and 'exclusive or', defined as follows. In
an 'and' relationship, the effect of having the risk-enhanc-
ing genotypes at both SNP loci is larger than the sum of
the single-locus effects. In an 'or' relationship, the effect of
having the risk-enhancing genotype at both loci is smaller
than the sum of the single-locus effects. In the final type
of interaction, named 'exclusive or', the effect of having
the risk-enhancing genotype at both loci is smaller than
that of having a risk-enhancing genotype at only one
locus. For each SNP pair, each of these configurations
gives rise to a contingency table, classified by genotype
group (risk-enhancing or risk-reducing) and phenotype
(case or control). These contingency tables were evalu-
ated, and the configuration with the lowest P-value for
association with the phenotype was identified. This con-
figuration indicated the type of interaction between the
two loci in question.
Results
Data checking
Although controls were selected from the same geo-
graphic area as the cases, a test was conducted to deter-
mine the presence of any latent population stratification.
The lambda statistic of Devlin et al. [19], calculated on
4,250 SNPs distributed over the whole genome, showed
no evidence of stratification (population heterogeneity,
overdispersion: Genotypic exact lambda = 1.061, Allelic
exact lambda = 1.000), indicating that no genomic-con-
trol adjustment is required when performing tests of gen-
otypic and allelic association on these subjects.
Of 374 SNPs submitted for genotyping, 3 were dropped
from analysis due to monomorphism in cases and con-
trols, and another 6 were dropped due to departure from
Hardy-Weinberg Equilibrium (P < 0.001). Among the
remaining SNPs, the proportion of individuals success-
fully genotyped ranged from 0.804 to 0.99, with a median
of 0.97. A subset of the individuals studied was genotyped
in duplicate, giving a total of 14,323 duplicate genotypes.
Of these, only 2 (= 0.014%) were inconsistent. The 365
SNPs retained, located in 8 genes, were subjected to sin-
gle-point analysis. The number of SNPs per gene is given
in Table 2. The median frequency of the minor allele
among the SNPs analysed was 22.9 %, but there were 35
SNPs (9.6% of those analysed) for which the minor allele
frequency was less than 5%. These SNPs, selected prior to
the availability of the HapMap [20], are less informative
than the others; however, as they do provide some addi-
tional information they were retained in the analysis.
Single-point results
Both allelic and genotypic tests of association were con-
ducted. Detailed results are provided in Additional file 1.
Significant results (P < 0.05) were observed in five genes,
namely NRG1, NRG2, NRG3, EGFR and ERBB4. These
confirmed previous findings on NRG1 and ERBB4 and
suggest possible involvement also of NRG2, NRG3 and
EGFR. Borderline evidence of association (P < 0.10) was
observed for one SNP in ERBB2. Haplotypic tests of asso-
ciation (not shown) provided similar results to the single-
point results described here. If none of the 365 single
SNPs were associated with the disease status (the null
hypothesis), we would expect 18 SNPs to be significant at
the 0.05 level and 37 SNPs to be significant at the 0.10
level on an allelic test. For the allelic test there were 34
SNPs significant at the 0.05 level (9.3%) and 59 SNPs sig-
nificant at the 0.10 level (16.2%). For the genotypic test
there were 24 SNPs significant at the 0.05 level (6.6%)
and 62 SNPs significant at the 0.10 level (17.0%). This
excess of significantly associated SNPs, beyond the num-
Table 2: Polymorphism in genes in the families NRG and ErbB investigated in this study.
Gene Chromosome Size (kb) No. of analysable SNPs No. of SNPs with p < 0.101 No. of SNPs with p < 0.051
NRG1 8 1120 94 22 (23%) 11 (12%)
NRG2 5 196 16 2 (13%) 1 (6%)
NRG3 10 1110 105 21 (20%) 10 (10%)
NRG4 15 70 9 0 0
EGFR 7 188 22 7 (32%) 6 (27%)
ERBB2 17 29 4 1 (25%) 0
ERBB3 12 23 6 0 0
ERBB4 2 1160 109 26 (24%) 14 (13%)
1 Either genotypic test or allelic test of association.Behavioral and Brain Functions 2007, 3:31 http://www.behavioralandbrainfunctions.com/content/3/1/31
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bers expected by chance when accounting for the multiple
tests, provides evidence that some of these associations
are real.
The distribution of evidence for single-point association
with schizophrenia, and linkage disequilibrium (LD),
over gene NRG1 are presented in Fig. 2. In this figure, the
magnitude of association of each SNP with schizophrenia
is indicated by the log-transformed P-value. For the sake
of simplicity, only values arising from the genotypic exact
test are shown; allelic test results followed a very similar
pattern. Across both tests, eleven SNPs in this gene
showed significant genotypic association with schizo-
phrenia (P < 0.05), and in three instances the association
was highly significant (P < 0.01) (see Additional file 1:
SNP RS776401: map position 031836504 on Chr 8, risk
genotype odds ratio (OR) = 1.461, 95% confidence inter-
val (CI) 1.160–1.840; SNP RS1383887: map position
031872698, OR = 1.589, CI 1.213–2.081; SNP RS-
GSK8116812: map position 032741837, OR = 1.651, CI
1.242–2.196). A putatively functional SNP in Exon 2, cod-
ing a non-synonymous (Gly/Arg) change, showed allelic
association to schizophrenia with P  = 0.0279 (SNP
RS3924999: map position 032572900, OR = 1.302, CI
1.028–1.648). It is possible that the cluster of associations
observed at the 3' end of the gene, to the right of the fig-
ure, has arisen through LD with this non-synonymous
change or another underlying functional variant. Further
evidence of association is seen at the 5' end of the gene,
closer to Exon 1. The latter associations fall beyond the
apparent reach of LD.
The corresponding information for gene ERBB4 is pre-
sented in Fig. 3. In this gene, fourteen SNPs were signifi-
cantly associated with schizophrenia by either the allelic
or genotypic test, including one allelic test result which
was highly significant (P < 0.01: SNP RS6754674: map
position 213033762 on Chr 2, OR = 1.387, CI 1.056–
1.822). Again, the graph of genotypic test results shows
strong evidence of association occurring most commonly
at the two ends of the gene, particularly at the 5'-end, to
the right of the figure, although the pattern is not as clear
as in the case of NRG1. This region of the gene represents
a 0.15 Mb region of moderate LD, so it is possible that a
single underlying variant, in LD with all of the SNPs that
show significant association, accounts for the observed
association in this region.
The corresponding information for genes NRG2, NRG3,
EGFR and ERBB2 is presented in Fig. 4, except that the LD
maps are omitted for brevity. A single SNP in NRG2
showed significant genotypic association with schizo-
phrenia (SNP RS2936651: map position 139401129 on
Chr 5, OR = 2.081, CI 1.156–3.745). This finding was cor-
roborated by a significant allelic test result also. Ten SNPs
were significantly associated in NRG3, including one
which was highly significantly associated (P < 0.01) by the
allelic test (RS3924461: map position 084423371 on
Chr10, OR = 1.283, CI 1.077–1.529). The pattern of LD in
this gene (results not shown) is highly localised, similar to
that in NRG1, so the observation of association from spa-
tially separated SNPs may have arisen by chance or may
suggest the presence of different functional variants
within the same gene. The spatial pattern of association is
not related to the distribution of the exons in this gene. Six
SNPs in EGFR were significantly associated with schizo-
phrenia, however, all fell in the range 0.01 <P < 0.05. Only
four SNPs were studied in ERBB2, and none of these was
found to be significantly associated with schizophrenia.
Interaction analysis results
As summarised in Table 2, 79 SNPs were identified which
had a P-value from an allelic or genotypic test that was less
than 0.10 (details are given in Additional file 2). These
SNPs were contained in the 6 genes considered above,
namely NRG1, NRG2, NRG3, EGFR, ERBB2, and ERBB4.
All pairs of these SNPs that are at least 0.5 cM apart on an
interpolated Decode genetic map [21] were tested for
interaction effects in a logistic regression interaction anal-
ysis.
A total of 2640 statistical tests for pair-wise interactions
were performed (details of results are given in Additional
file 2). Of these, 212 were significant at the 5% level: that
is 8.03% of all tests were significant compared to 132 (=
5% of 2640) expected by chance if the null hypothesis of
no interaction were true for all pairs of SNPs tested. If all
the tests performed were mutually independent the prob-
ability that 212 or more would be significant by chance is
2.575 × 10-11 (P(R ≥ 212) where R~binomial(N = 2640, p
= 0.05)). The true probability of such an outcome is cer-
tain to be larger, due to non-independence among the
tests: nevertheless, this result provides convincing evi-
dence that some of the observed interactions are real. The
significance levels presented here are not adjusted for
multiple testing: a Bonferroni correction would be inap-
propriate due to non-independence among the tests, and
the multiple-testing issue is addressed by the comparison
of observed and expected numbers of significant tests pre-
sented above. None of the significant results obtained
would survive the Bonferroni correction.
Table 3 gives the percentage of significant interactions for
each gene combination; the corresponding counts are
given in brackets. There are four gene combinations in
which the percentage of significant interactions is sub-
stantially higher than the 5% expected by chance, viz. the
two-gene combinations NRG1-NRG2, NRG1-NRG3 and
NRG2-EGFR, and the single large gene ERBB4. The per-
centages of significant interactions for combinationsBehavioral and Brain Functions 2007, 3:31 http://www.behavioralandbrainfunctions.com/content/3/1/31
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NRG1-NRG2 and NRG2-EGFR are based on a small
number of tests and should therefore be treated with cau-
tion, but the percentages for NRG1-NRG3 and ERBB4 are
based on substantial numbers.
The next step towards the identification of a mechanism
to account for the statistical interactions is the identifica-
tion of the type of each significant interaction. This was
performed by pair-wise combination analysis (see Meth-
ods). Fig. 5 illustrates the distribution of the three types of
interaction over the four gene combinations with a large
percentage of significant interactions. The frequencies of
and-type and or-type interactions are fairly similar. This
might be expected, as the patterns of results that corre-
spond to these two types of interaction are complemen-
tary, and equally likely to occur by chance. Interactions of
the xor-type are rare: indeed, they are observed only in the
two gene combinations that gave rise to a fairly large sam-
ple of significant interactions. This also might be
expected, as it corresponds to a complex biological mech-
anism and to a rather specific pattern of results that is rel-
atively unlikely to occur by chance.
Discussion
In this manuscript we present confirmation of earlier pub-
lished associations between schizophrenia and the genes
NRG1 and ERBB4. We build a new, compelling picture of
pathway involvement by showing that associations exist
with additional gene family-members, namely EGFR,
NRG2, and NRG3. Lastly, we present statistical evidence
of gene epistasis, consistent with a highly complex biolog-
ical pathway of schizophrenia susceptibility. This is the
first time that the roles and inter-relationships of the ERBB
and NRG gene families as a whole have been investigated
in relation to schizophrenia and our approach sets a prec-
edent in the investigation of common complex diseases.
Genotypic single-point association test results and LD over NRG1 Figure 2
Genotypic single-point association test results and LD over NRG1. In the plot of -log10(P) v. map position, horizontal 
dashed lines are at P = 0.05, 0.01 and 0.001. Vertical dashed lines are at 20 kb intervals. The region covered by the gene is indi-
cated in the centre of the figure by a horizontal line, with an arrow head indicating the direction of transcription. A crossing 
vertical line indicates the position of each exon. At the base of the figure, LD between SNP loci is indicated by shading. White: 
r2 = 0; black: r2 = 1.
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Clear evidence for gene-gene interaction was detected for
gene combinations NRG1-NRG2, NRG1-NRG3 and
EGFR-NRG2, and suggestive evidence was also seen for
ERBB4-NRG1, ERBB4-NRG2, ERBB4-NRG3 and ERBB4-
ERBB2. Evidence of intragenic interaction was seen for
SNPs in ERBB4. Of the 2640 tests for pair-wise interac-
tion, 212 were significant at the 5% level, which is sub-
stantially more than the 131 expected by chance. This
large number of low P-values may be partly explained by
non-independence among tests. However, it may also
indicate that some of the 79 SNPs studied interact to mod-
ulate susceptibility to schizophrenia.
Numerous studies have investigated the association
between schizophrenia and NRG1 (reviewed in [22]). A
comparison of the associations generated in the current
study with those previously published shows good agree-
ment. Associations that we observed at the 5' region of
NRG1 overlap with those found by Stefansson et al. [3,4],
Corvin et al. [23], Li et al. [24], Zhao et al. [25] and Petry-
shen et al. [26]. Similarly, the associations we observed at
the 3' end of the gene overlap with those found by Yang et
al. [27], Li et al. [23], Petryshen et al. [25] and Lachmann
et al. [28]. Two polymorphisms in our study directly rep-
licate these associations: the putatively functional SNP
rs3924999 was found to be associated with schizophrenia
in a Han Chinese family study conducted by Yang et al.
[26]. This SNP was also tested in a Caucasian study of 136
families by Duan et al. [29], but was not significant.
Rs2466049 was significant as part of a haplotype found in
a Caucasian family by Petryshen et al. [25].
For the ERBB4 gene, four polymorphisms (rs3748962,
rs839523, rs2054617 and rs6435711) screened in this
study were also analysed by Silberberg et al. [8]. However,
none of the individual SNP associations observed in the
Genotypic single-point association test results and LD over ERBB4 Figure 3
Genotypic single-point association test results and LD over ERBB4. In the plot of -log10(P) v. map position, horizontal 
dashed lines are at P = 0.05, 0.01 and 0.001. Vertical dashed lines are at 20 kb intervals. The region covered by the gene is indi-
cated in the centre of the figure by a horizontal line, with an arrow head indicating the direction of transcription. A crossing 
vertical line indicates the position of each exon. At the base of the figure, LD between SNP loci is indicated by shading. White: 
r2 = 0; black: r2 = 1.
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previous study was replicated here. As no underlying func-
tional variant has been identified for ERBB4, this lack of
association at the SNP level is unsurprising and is consist-
ent with a heterogeneous haplotypic background across
studies. It is worth noting also that non-coding polymor-
phisms might lead to dysregulation of ErbB4 expression
levels, a hypothesis corroborated by the Silberberg et al.
[8] study, which found enhanced expression of the ERBB4
Jm-a CYT-1 isoform (one of four splice variants, see [30])
in schizophrenic patients. The altered balance of ErbB4
isoforms could lead to variations in homo- and het-
erodimer formation and thus in downstream signalling
pathways.
In addition to providing further evidence of NRG1 and
ERBB4 associations to schizophrenia, our study is the first
to suggest possible involvement of three additional genes
from the NRG and ERBB gene families, i.e. NRG2, NRG3
and EGFR (ERBB1). It is interesting to note that we only
detected evidence for association of NRG genes which are
expressed in the central nervous system, namely NRG1,
NRG2 and the nervous-system-specific NRG3 [31],
whereas NRG4, which is mainly expressed in pancreas
and absent from the brain [32] was not found to be asso-
ciated to schizophrenia.
To our knowledge, an association of EGFR to schizophre-
nia has not previously been investigated. Association of a
polymorphism in EGF (one of the six EGFR ligands, Fig.
1) with schizophrenia was reported in Finnish men [33],
but not replicated in a Japanese population [34]. Further
support for a possible role of EGF and EGFR in the disease
comes from findings of abnormal expression of these
genes in the forebrain and serum of schizophrenic
Genotypic single-point association test results and LD over NRG2, NRG3, EGFR and ERBB2 Figure 4
Genotypic single-point association test results and LD over NRG2, NRG3, EGFR and ERBB2. In the plot of -
log10(P) v. map position, horizontal dashed lines are at P = 0.05, 0.01 and 0.001. Vertical dashed lines are at 20 kb intervals. The 
region covered by the gene is indicated in the centre of the figure by a horizontal line, with an arrow head indicating the direc-
tion of transcription. A crossing vertical line indicates the position of each exon. Behavioral and Brain Functions 2007, 3:31 http://www.behavioralandbrainfunctions.com/content/3/1/31
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patients [35]. EGFR is usually omitted in reviews on NRG-
ERBB signalling, although it is well-established that ErbB4
can interact with and cross-phosphorylate EGFR upon
neuregulin-binding [36-39]. Furthermore, EGFR and
ERBB4 show partially overlapping temporal and spatial
mRNA expression in several brain areas, such as cortex,
striatum, cerebellum and hippocampus, and are coex-
pressed in GABAergic interneurons [40,41]. Therefore, it is
very likely that EGFR/ErbB4 heterodimers mediate impor-
tant functions in the developing and adult central nervous
system in vivo. Whilst we limited this study to the NRG
and ERBB gene families, it would be interesting to investi-
gate association of the additional EGFR and ErbB4 ligands
(see Fig. 1).
The significant gene-gene interactions reported in this
study support our hypothesis of pathway involvement in
schizophrenia. These genes have related functions and, for
example, the NRG1-NRG2 and NRG1-NRG3 interactions
may suggest competition between these ligands for a
receptor. The NRG2-EGFR interaction is superficially
more difficult to explain since NRG2 is a ligand for ErbB3
and ErbB4 and does not usually recognize EGFR directly
or with high affinity [42-44]. However, a recent study
reports that a single amino acid change in the EGFR lig-
and-binding domain dramatically increases the receptor
affinity for NRG2β which can then induce potent stimula-
tion of EGFR signalling [45]. The interactions within the
ERBB4 gene suggest that combinations of particular geno-
types may result in modified receptor activity, leading to
altered risk of schizophrenia.
Such suggestions concerning possible mechanisms of
interaction remain speculative until the reality of these
interactions has been established biologically and the
effect of each two-locus genotype on the phenotype is
understood. A follow-up study currently underway, using
independent cases and controls, will clarify which of these
interactions can be replicated and may generate further
hypotheses regarding the nature of the interactions. It will
be interesting also to investigate whether observed associ-
ations or their interactions correspond to particular phe-
notypically defined patient sub-groups. The strong
evidence of genetic associations and interactions reported
here provides ample justification for such an enquiry.
Conclusion
This study confirms previously published associations
between schizophrenia and NRG1 and ERBB4, and points
to three other members of the NRG and ERBB gene fami-
lies (EGFR, NRG2 and NRG3) as potential schizophrenia
susceptibility genes. Furthermore, the study presents evi-
dence for inter- and intragenic pair-wise interaction
between loci in genes of both families (NRG1-NRG2,
NRG2-EGFR, NRG1-NRG3 and ERBB4-ERBB4). These
extensive genetic inter-relationships observed among lig-
ands and receptors of the ERBB and NRG gene families
reflect the complexity of their interactions at the molecu-
lar level. The influence of so many closely related genetic
factors on the potential development of disease patho-
physiology has rarely, if ever, been demonstrated before
and may partially explain the difficulty in arriving at an
Table 3: Percentages of pair-wise interactions that were significant (P < 0.05), classified by the gene(s) in which the interacting SNPs 
lie. Gene combinations in which there are substantially more significant interactions than the 5% expected by chance are indicated in 
bold. The counts that contribute to each percentage are also shown in parentheses as a fraction. The presence of "-" in the table 
indicates that no pairs of SNPs in this gene are 0.5 cM apart.
NRG1 NRG2 NRG3 EGFR ERBB2 ERBB4
NRG1 5.8% (6/103) 13.6% (6/44) 11.7% (54/462) 4.5% (7/154) 0.0% (0/22) 7.9% (45/572)
NRG2 - 4.8% (2/42) 14.3% (2/14) 0.0% (0/2) 7.7% (4/52)
NRG3 5.7% (6/105) 2.0% (3/147) 0.0% (0/21) 8.4% (46/546)
EGFR - 0.0% (0/7) 5.5% (10/182)
ERBB2 -7 . 7 %  ( 2 / 2 6 )
ERBB4 13.7% (19/139)
Distribution of the types of pair-wise interaction in gene  combinations with a large percentage of significant interac- tions Figure 5
Distribution of the types of pair-wise interaction in 
gene combinations with a large percentage of signifi-
cant interactions. The total in each column corresponds 
to the number of significant interactions presented in Table 
3, i.e. the numerator of the fraction presented in that table 
for the gene combination in question.Behavioral and Brain Functions 2007, 3:31 http://www.behavioralandbrainfunctions.com/content/3/1/31
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overarching genetic hypothesis of the etiology of schizo-
phrenia. In future studies, it will be important to replicate
our new findings in an independent cohort and to under-
stand the underlying biological mechanisms of the single-
locus associations as well as the interactions among differ-
ent loci.
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